Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.

Mesa RA, Kantarjian H, Tefferi A, Dueck A, Levy R, Vaddi K, Erickson-Viitanen S, Thomas DA, Cortes J, Borthakur G, Pardanani AD, Estrov Z, Verstovsek S

Clinical and laboratory features of myelofibrosis and limitations of current therapies.

Gregory SA, Mesa RA, Hoffman R, Shammo JM

Transplantation for myelofibrosis: time for a randomized trial.

Mesa RA

Blood consult: resistant and progressive essential thrombocythemia.

Tibes R, Mesa RA

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.

Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Harrison CN, Radia D, Mesa RA

Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?

Tibes R, Mesa RA

The renaissance of interferon therapy for the treatment of myeloid malignancies.

Kiladjian JJ, Mesa RA, Hoffman R

Future therapies for the myeloproliferative neoplasms.

Scherber R, Mesa RA

A phase-2 trial of low-dose pomalidomide in myelofibrosis.

Begna KH, Mesa RA, Pardanani A, Hogan WJ, Litzow MR, McClure RF, Tefferi A

International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens.

Thapaliya P, Tefferi A, Pardanani A, Steensma DP, Camoriano J, Wu W, Geyer S, Mesa RA